Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

BACKGROUND: Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA...

Descripción completa

Detalles Bibliográficos
Autores principales: Belderbos, Bodine P.S., de Wit, Ronald, Hoop, Esther Oomen-de, Nieuweboer, Annemieke, Hamberg, Paul, van Alphen, Robbert J., Bergman, André, van der Meer, Nelly, Bins, Sander, Mathijssen, Ron H.J., van Soest, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739748/
https://www.ncbi.nlm.nih.gov/pubmed/29290963
http://dx.doi.org/10.18632/oncotarget.22474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739748/
https://www.ncbi.nlm.nih.gov/pubmed/29290963
http://dx.doi.org/10.18632/oncotarget.22474

Ejemplares similares